Monoclonal antibody utilization characteristics in patients with multiple myeloma.

MLA

Ailawadhi, Sikander, et al. “Monoclonal Antibody Utilization Characteristics in Patients with Multiple Myeloma.” Anti-Cancer Drugs, vol. 30, no. 8, Sept. 2019, pp. 859–65. EBSCOhost, https://doi.org/10.1097/CAD.0000000000000810.

APA

Ailawadhi, S., Sher, T., Azzouqa, A.-G., Meghji, Z., Jain, T., Jani, P., Ahmed, S., Diehl, N., Roy, V., Shah, V., Hodge, D., Ailawadhi, M., Alegria, V. R., Paulus, A., Chanan-Khan, A., & Fonseca, R. (2019). Monoclonal antibody utilization characteristics in patients with multiple myeloma. Anti-Cancer Drugs, 30(8), 859–865. https://doi.org/10.1097/CAD.0000000000000810

Chicago

Ailawadhi, Sikander, Taimur Sher, Abdel-Ghani Azzouqa, Zahara Meghji, Tania Jain, Prachi Jani, Salman Ahmed, et al. 2019. “Monoclonal Antibody Utilization Characteristics in Patients with Multiple Myeloma.” Anti-Cancer Drugs 30 (8): 859–65. doi:10.1097/CAD.0000000000000810.